Cargando…
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
[Image: see text] Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of ne...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Chemical Society
2021
|
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043200/ https://www.ncbi.nlm.nih.gov/pubmed/34056089 http://dx.doi.org/10.1021/acscentsci.1c00080 |
| _version_ | 1783678264259117056 |
|---|---|
| author | Watanabe, Yasunori Mendonça, Luiza Allen, Elizabeth R. Howe, Andrew Lee, Mercede Allen, Joel D. Chawla, Himanshi Pulido, David Donnellan, Francesca Davies, Hannah Ulaszewska, Marta Belij-Rammerstorfer, Sandra Morris, Susan Krebs, Anna-Sophia Dejnirattisai, Wanwisa Mongkolsapaya, Juthathip Supasa, Piyada Screaton, Gavin R. Green, Catherine M. Lambe, Teresa Zhang, Peijun Gilbert, Sarah C. Crispin, Max |
| author_facet | Watanabe, Yasunori Mendonça, Luiza Allen, Elizabeth R. Howe, Andrew Lee, Mercede Allen, Joel D. Chawla, Himanshi Pulido, David Donnellan, Francesca Davies, Hannah Ulaszewska, Marta Belij-Rammerstorfer, Sandra Morris, Susan Krebs, Anna-Sophia Dejnirattisai, Wanwisa Mongkolsapaya, Juthathip Supasa, Piyada Screaton, Gavin R. Green, Catherine M. Lambe, Teresa Zhang, Peijun Gilbert, Sarah C. Crispin, Max |
| author_sort | Watanabe, Yasunori |
| collection | PubMed |
| description | [Image: see text] Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibodies that they produce appropriately processed and assembled viral antigen that mimics that observed on the SARS-CoV-2 virus. Here, we describe the structure, conformation, and glycosylation of the S protein derived from the adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate native-like post-translational processing and assembly, and reveal the expression of S proteins on the surface of cells adopting the trimeric prefusion conformation. The data presented here confirm the use of ChAdOx1 adenovirus vectors as a leading platform technology for SARS-CoV-2 vaccines. |
| format | Online Article Text |
| id | pubmed-8043200 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | American Chemical Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80432002021-04-13 Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine Watanabe, Yasunori Mendonça, Luiza Allen, Elizabeth R. Howe, Andrew Lee, Mercede Allen, Joel D. Chawla, Himanshi Pulido, David Donnellan, Francesca Davies, Hannah Ulaszewska, Marta Belij-Rammerstorfer, Sandra Morris, Susan Krebs, Anna-Sophia Dejnirattisai, Wanwisa Mongkolsapaya, Juthathip Supasa, Piyada Screaton, Gavin R. Green, Catherine M. Lambe, Teresa Zhang, Peijun Gilbert, Sarah C. Crispin, Max ACS Cent Sci [Image: see text] Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibodies that they produce appropriately processed and assembled viral antigen that mimics that observed on the SARS-CoV-2 virus. Here, we describe the structure, conformation, and glycosylation of the S protein derived from the adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate native-like post-translational processing and assembly, and reveal the expression of S proteins on the surface of cells adopting the trimeric prefusion conformation. The data presented here confirm the use of ChAdOx1 adenovirus vectors as a leading platform technology for SARS-CoV-2 vaccines. American Chemical Society 2021-04-02 2021-04-28 /pmc/articles/PMC8043200/ /pubmed/34056089 http://dx.doi.org/10.1021/acscentsci.1c00080 Text en © 2021 The Authors. Published by American Chemical Society Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Watanabe, Yasunori Mendonça, Luiza Allen, Elizabeth R. Howe, Andrew Lee, Mercede Allen, Joel D. Chawla, Himanshi Pulido, David Donnellan, Francesca Davies, Hannah Ulaszewska, Marta Belij-Rammerstorfer, Sandra Morris, Susan Krebs, Anna-Sophia Dejnirattisai, Wanwisa Mongkolsapaya, Juthathip Supasa, Piyada Screaton, Gavin R. Green, Catherine M. Lambe, Teresa Zhang, Peijun Gilbert, Sarah C. Crispin, Max Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine |
| title | Native-like SARS-CoV-2 Spike Glycoprotein Expressed
by ChAdOx1 nCoV-19/AZD1222 Vaccine |
| title_full | Native-like SARS-CoV-2 Spike Glycoprotein Expressed
by ChAdOx1 nCoV-19/AZD1222 Vaccine |
| title_fullStr | Native-like SARS-CoV-2 Spike Glycoprotein Expressed
by ChAdOx1 nCoV-19/AZD1222 Vaccine |
| title_full_unstemmed | Native-like SARS-CoV-2 Spike Glycoprotein Expressed
by ChAdOx1 nCoV-19/AZD1222 Vaccine |
| title_short | Native-like SARS-CoV-2 Spike Glycoprotein Expressed
by ChAdOx1 nCoV-19/AZD1222 Vaccine |
| title_sort | native-like sars-cov-2 spike glycoprotein expressed
by chadox1 ncov-19/azd1222 vaccine |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043200/ https://www.ncbi.nlm.nih.gov/pubmed/34056089 http://dx.doi.org/10.1021/acscentsci.1c00080 |
| work_keys_str_mv | AT watanabeyasunori nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT mendoncaluiza nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT allenelizabethr nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT howeandrew nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT leemercede nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT allenjoeld nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT chawlahimanshi nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT pulidodavid nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT donnellanfrancesca nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT davieshannah nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT ulaszewskamarta nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT belijrammerstorfersandra nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT morrissusan nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT krebsannasophia nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT dejnirattisaiwanwisa nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT mongkolsapayajuthathip nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT supasapiyada nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT screatongavinr nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT greencatherinem nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT lambeteresa nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT zhangpeijun nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT gilbertsarahc nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine AT crispinmax nativelikesarscov2spikeglycoproteinexpressedbychadox1ncov19azd1222vaccine |